Business
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock. All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, t
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","alt":"NeuroOne Medical Technologies Corporation","displaySize":"","headline":null,"caption":"NeuroOne Medical Technologies Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/819fe13d4f4c15d1a815f2aae4dd578b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pp0tg2T4IB9hXCYxVLu0sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/819fe13d4f4c15d1a815f2aae4dd578b","width":300,"height":48}},"lazy":false},{"type":"text","content":"EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.","length":386,"tagName":"p"},{"type":"text","content":"All of the shares of common stock to be sold in the proposed offering will be sold by the Company. In addition, the Company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.","length":463,"tagName":"p"},{"type":"text","content":"Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the proposed offering.","length":99,"tagName":"p"},{"type":"text","content":"The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-279871) that was declared effective by the U.S. Securities and Exchange Commission (“SEC”), on August 16, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000 or by email at [email protected].","length":586,"tagName":"p"},{"type":"text","content":"This press release does not and shall not...